No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells

Cytotherapy

Volumn 10, Issue 3, 2008, Pages 238-242

  Sundin, M ^a   Remberger, M ^a,b   Lonnies H ^a   Sundberg, B ^a   Ringden O ^a,b   Le Blanc, K ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Immunosuppression; Qraft versus host disease; Stem cell

Indexed keywords

ADULT; ARTICLE; BIOFILTER; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL GROWTH; CELL PROLIFERATION; CELL TYPE; CHILD; CONTROLLED STUDY; DONOR; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STROMAL CELL; MIXED LYMPHOCYTE CULTURE; MULTIPOTENT STEM CELL; PHENOTYPE; PRIORITY JOURNAL; ADOLESCENT; COMPARATIVE STUDY; CYTOLOGY; FILTRATION; INFANT; MESODERM; MIDDLE AGED; PRESCHOOL CHILD; STROMA CELL;

ADOLESCENT; BONE MARROW CELLS; CELL PROLIFERATION; CHILD, PRESCHOOL; FEMALE; FILTRATION; FLOW CYTOMETRY; HUMANS; INFANT; MALE; MESODERM; MIDDLE AGED; PHENOTYPE; STROMAL CELLS;

EID: 42449143490     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240801965164     Document Type: Article

References (24)

1. Horwitz, EM, Blanc, K Le and Dominici, M. (2005) Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy, 7, pp. 393-395.
2. Blanc, K Le and Pittenger, M. (2005) Mesenchymal stem cells: Progress toward promise. Cytotherapy, 7, pp. 36-45.
3. Blanc, K Le and Ringden, O. (2007) Immunomodulation by mesenchymal stem cells and clinical experience. J Int Med, 262, pp. 509-525.
4. Blanc, K Le, Rasmusson, I. and Sundberg, B. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363, pp. 1439-1441.
5. Ringden, O., Uzunel, M. and Rasmusson, I. (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81, pp. 1390-1397.
6. Bruder, SP, Jaiswal, N. and Haynesworth, SE. (1997) Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem, 64, pp. 278-294.
7. Friedenstein, AJ, Petrakova, KV and Kurolesova, AI (1968) Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation, 6, pp. 230-247.
8. Blanc, K Le, Tammik, C. and Rosendahl, K. (2003) HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 31, pp. 890-896.
9. Pittenger, MF, Mackay, AM and Beck, SC (1999) Multilineage potential of adult human mesenchymal stem cells. Science, 284, pp. 143-147.
10. Prockop, DJ. (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276, pp. 71-74.
11. Tyndall, A., Walker, UA and Cope, A. (2007) Immunomodulatory properties of mesenchymal stem cells: A review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arth Res Ther, 9, p. 301.
12. Giordano, A., Galderisi, U. and Marino, IR. (2007) From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol, 211, pp. 27-35.
13. Dominietto, A., Raiola, AM and van Lint, MT (2001) Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: Graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol, 112, pp. 219-227.
14. Gorin, NC, Labopin, M. and Rocha, V. (2003) Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow. Blood, 102, pp. 3043-3051.
15. Sierra, J., Storer, B. and Hansen, JA (1997) Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood, 89, pp. 4226-4235.
16. Storb, R., Prentice, RL and Thomas, ED. (1977) Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. New Engl J Med, 296, pp. 61-66.
17. Bortin, MM, Gale, RP and Kay, HE (1983) Bone marrow transplantation for acute myelogenous leukemia. Factors associated with early mortality. JAMA, 249, pp. 1166-1175.
18. Ringden, O. and Nilsson, B. (1985) Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation, 40, pp. 39-44.
19. Paulin, T. (1992) Importance of bone marrow cell dose in bone marrow transplantation. Clin Transplant, 6, pp. 48-54.
20. Blazsek, I., Liu, XH and Anjo, A. (1995) The hematon, a morphogenetic functional complex in mammalian bone marrow, involves erythroblastic islands and granulocytic cobblestones. Exp Hematol, 23, pp. 309-319.
21. Blazsek, I., Misset, JL and Benavides, M. (1990) Hematon, a multicellular functional unit in normal human bone marrow: Structural organization, hemopoietic activity, and its relationship to myelodysplasia and myeloid leukemias. Exp Hematol, 18, pp. 259-265.
22. Vicente, D., Podesta, M. and Pitto, A. (2006) Progenitor cells trapped in marrow filters can reduce GvHD and transplant mortality. Bone Marrow Transplant, 38, pp. 111-117.
23. Moller, G. (1970) Induction of DNA synthesis in human lymphocytes: interaction between non-specific mitogens and antigens. Immunology, 19, pp. 583-598.
24. Sundin, M., Orvell, C. and Rasmusson, I. (2006) Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant, 37, pp. 1051-1059.